Neoadjuvant RCT Versus CT for Patients With Locally Advanced Potentially Resectable Adenocarcinoma of the GEJ

  • STATUS
    Recruiting
  • End date
    Aug 5, 2028
  • participants needed
    340
  • sponsor
    Universitätsmedizin Mannheim
Updated on 19 February 2024
estrogen
calcium
renal function
neutrophil count
docetaxel
oxaliplatin
adenocarcinoma
fluorouracil
leucovorin
hormonal contraception
aptt
progestogen
kidney function test
adenocarcinoma of the gastroesophageal junction
tubal occlusion
intrauterine device (iud)
flot
flot regimen

Summary

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone fr patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)

Description

The RACE trial seeks to demonstrate superiority of preoperative FLOT induction chemotherapy followed by preoperative radiochemotherapy and postoperative FLOT chemotherapy over perioperative FLOT chemotherapy without radiotherapy in patients with adenocarcinoma of the gastroesophageal junction undergoing adequate oncological surgery.

Eligible patients will be randomly allocated to one of two treatment groups, i.e. preoperative chemotherapy (Arm A) or preoperative chemotherapy with subsequent preoperative radiochemotherapy (arm B), both followed by resection and postoperative completion of chemotherapy. Randomization will occur in a 1:1 ratio with stratification by primary tumor site (Siewert I vs. Siewert II/III).

Arm A:

Patients randomized to Arm A (control arm) will be treated with four preoperative cycles of FLOT. Cycles will be repeated every two weeks. The preoperative chemotherapy duration in Arm A is eight weeks. Surgical resection will follow 4-6 weeks after day 1 of the last cycle of neoadjuvant therapy. Postoperative chemotherapy will start 6-12 weeks after surgery and consists of another four cycles of FLOT every two weeks. The total treatment period is 25-32 weeks.

Arm B:

Patients randomized in Arm B (experimental arm) will be treated with two cycles of FLOT every two weeks. Radiochemotherapy will start three weeks after day 1 of the second cycle and consists of oxaliplatin and infusional 5-fluorouracil plus concurrent radiotherapy given to a dose of 45 Gy (25 daily fractions with 1.8 Gy) over five weeks. The preoperative treatment duration is 10 weeks. Surgical resection will follow 4-6 weeks after last treatment with chemotherapy / radiation. Postoperative chemotherapy will start 6-12 weeks after surgery and consists of four cycles of FLOT every two weeks. The total treatment period is 26-33 weeks.

Details
Condition Gastroesophageal Junction Adenocarcinoma
Age 18years - 100years
Treatment Radiation, Oxaliplatin, Calcium folinate, Docetaxel, 5-Fluorouracil, Oxaliplatin during radiotherapy, 5-Fluorouracil during radiotherapy
Clinical Study IdentifierNCT04375605
SponsorUniversitätsmedizin Mannheim
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven, locally advanced and potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) (Siewert I- III) that is: cT3-4, any N, M0 or cT2 N+, M0 according to AJCC 8th edition
Patients must be candidates for potential curative resection as determined by the treating surgeon
ECOG performance status 0-1
Age 18 years or above
Adequate hematologic function with absolute neutrophil count (ANC) 1.5 x 10^9/l, platelets 100 x 10^9/l and hemoglobin 9.0 mg/dl
INR <1.5 and aPTT<1.5 x upper limit of normal (ULN) within 7 days prior to starting study treatment
Adequate liver function as measured by serum transaminases (ASAT, ALAT) 2.5 x ULN and total bilirubin 1.5 x ULN
Adequate renal function with serum creatinine 1.5 x ULN
QTc interval (Bazett) 440 ms
Written informed consent obtained before randomization
Negative pregnancy test for women of childbearing potential within 7 days of commencing study treatment. Males and females of reproductive potential must agree to practice highly effective contraceptive measures during the study and for 6 months after the end of study treatment. Male patients must also agree to refrain from father a child during treatment and up to 6 months afterwards and additionally to use a condom during treatment period. Their female partner of childbearing potential must also agree to use an adequate contraceptive measure
There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently
formula for QTc interval calculation (Bazett): QTc= ((QT) " (ms)" )/(RR (sec))= ((QT) " (ms)" )/(60/(Frequence (1/min)))
highly effective (i.e. failure rate of <1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments)

Exclusion Criteria

Evidence of metastatic disease (exclusion of distant metastasis by CT of thorax and abdomen, bone scan or MRI [if osseous lesions are suspected due to clinical signs])
Past or current history (within the last 5 years prior to treatment start) of other malignancies. Patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible
Evidence of peripheral sensory neuropathy > grade 1 according to CTCAE version 4.03
Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled
Pregnant or lactating females
Patients medically unfit for chemotherapy and radiotherapy
Patients receiving any immunotherapy, cytotoxic chemotherapy or radiotherapy other than defined by the protocol. The participation in another clinical trial with the use of investigational agents, chemotherapy or radiotherapy during the trial is not permitted
Known hypersensitivity against 5-FU, leucovorin, oxaliplatin or docetaxel
Other known contraindications against 5-FU, leucovorin, oxaliplatin, or docetaxel
Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV
Clinically significant valvular defect
Other severe internal disease or acute infection
Peripheral polyneuropathy > NCI Grade II according to CTCAE version 4.03
Chronic inflammatory bowel disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study AnnotationsStudy Notes

Notes added here are public and can be viewed by anyone. Notes added here are only available to you and those who you share with.

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.